Other studies have confirmed the potential usefulness of NGAL measurement in the evaluation of early responses to therapy or in predicting different clinical outcomes with infliximab in Crohn disease [6] and intravenous immunoglobulin infusion in renal disease [23]. Here, LCN2 is linked to kidney disorder.